Results 121 to 130 of about 21,130 (289)

Modern management of primary B-cell immunodeficiencies

open access: yes, 2011
To cite this article: Hoernes M, Seger R, Reichenbach J. Modern management of primary B-cell immunodeficiencies. Pediatr Allergy Immunology 2011: 22: 758-769. ABSTRACT: B-cell defects constitute the majority of primary immunodeficiencies.
Seger, R   +5 more
core   +1 more source

Targeting KDM3B Elicits Anti‐tumor Immunity by Alleviating SHP1–mediated STING Suppression in Triple–Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
P3FI–90 treatment targets KDM3B, reshapes the epigenetic landscape, and suppresses SHP1 expression, thereby activating STING–TBK1–IRF3–type I IFN signaling pathway. Consequently, CD8+ T cells are recruited to the tumor site and activated to produce IFN–γ and GZMB, leading to the killing of TNBC cells.
Xiaolong Wang   +8 more
wiley   +1 more source

Melatonin Alleviates Graft Biliary Fibrosis by Inhibiting VIM+ Cholangiocyte Subcluster via Hypoxia/TGF‐β‐CREM‐VIM Axis

open access: yesAdvanced Science, EarlyView.
Single‐cell RNA sequencing verified the presence of the VIM+ biliary epithelial cell (BEC) in the bile ducts of NAS patients. The hypoxia/TGF‐β‐CREM‐VIM axis mediated phenotypic switch toward VIM+ BEC is validated using a hypoxia/TGF‐β‐stimulated cellular model, a rat liver transplantation model, BEC‐specific Crem conditional knockout rats, and BEC ...
Zhaoyi Wu   +14 more
wiley   +1 more source

AI‐Designed Cyclic Peptides Enable Controllable Modulation of the CD28 Immune Checkpoint

open access: yesAdvanced Science, EarlyView.
AI‐designed cyclic peptides enable controllable modulation of the CD28 immune checkpoint through reversible disruption of CD28‐CD80/CD86 interactions. The lead peptide, CIP‐3, suppresses T‐cell activation without intrinsic agonist activity, demonstrates dose‐dependent efficacy in a murine colitis model, and attenuates inflammatory cytokine production ...
Katarzyna Kuncewicz   +4 more
wiley   +1 more source

Management of a Patient with Cardiovascular Disease Should Include Assessment of Primary and Secondary Immunodeficiencies: Part 2—Secondary Immunodeficiencies

open access: yes
Background: Cardiovascular diseases are among the most common chronic diseases, generating high social and economic costs. Secondary immunodeficiencies occur more often than primary ones and may result from the co-occurrence of specific diseases ...
Agata Doligalska   +8 more
core   +1 more source

Clinical details of primary and secondary immunodeficiencies associated with Th17 deficiency.

open access: yes, 2016
Clinical details of primary and secondary immunodeficiencies associated with Th17 deficiency.
Yifang Gao (2625715)   +8 more
core   +1 more source

Innate immunodeficiencies: a group of primary immunodeficiencies predisposing exclusively to common diseases

open access: yesEgyptian Journal of Medical Human Genetics
Background Innate immune deficiencies can impair both cellular and humoral immune responses. In contrast, other immune functions may appear normal, leading to increased susceptibility to specific pathogens, such as severe viral infections or Mendelian ...
Marwa Refaat   +12 more
doaj   +1 more source

CCT2 Promotes Prostate Cancer Progression Through EIF3F‐Dependent Stabilization of FASN

open access: yesAdvanced Science, EarlyView.
ABSTRACT Prostate cancer (PCa) is increasingly recognized to be driven by dysregulated lipid metabolism. Although fatty acid synthase (FASN) is highly expressed in PCa, the mechanisms governing FASN protein stability and its functional integration into oncogenic lipid metabolism remain poorly defined.
Shun Xu   +13 more
wiley   +1 more source

ICON: The early diagnosis of congenital immunodeficiencies

open access: yes, 2014
Primary immunodeficiencies are intrinsic defects in the immune system that result in a predisposition to infection and are frequently accompanied by a propensity to autoimmunity and/or immunedysregulation.
Etzioni A   +18 more
core  

Gene therapy for primary immunodeficiencies: part 2

open access: yes, 2012
Gene therapy has become an attractive alternative therapeutic strategy to allogeneic transplant for primary immunodeficiencies (PIDs) owing to known genetic defects.
Seger, Reinhard   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy